title: Experimental treatment strategies in primary cutaneous T-cell lymphomas.
abstract: OBJECTIVE
  Cutaneous T-cell lymphoma (CTCL) comprises a heterogeneous group of malignancies derived from skin-homing or resident T cells. Effective treatments are limited, thus new therapies are in development to address the unmet medical need.
  
  
  RESULTS
  Recent studies uncovering the genetic alteration in cutaneous T-cell lymphoma have enhanced our understanding of the importance of the T-cell activation/survival pathways, dysregulated immune system, and the relevance of chromatin modification in the pathogenesis of CTCL. New advances in cancer immunomodulation such as with PD1/PD-L1 inhibitors and novel targeted antitumor therapies such as brentuximab vedotin and mogamulizumab as well as potential combination strategies are promising for improving clinical efficacy with manageable toxicity profile.
  
  
  CONCLUSIONS
  All these new therapeutic approaches have resulted in broadening the treatment landscape and a potential paradigm shift in the management of CTCL.
authors: Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
authors: Sima
authors: S
authors: Rozati
authors: Youn H
authors: YH
authors: Kim
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D000079963:Brentuximab Vedotin; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D018796:Immunoconjugates; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000079963:Brentuximab Vedotin; C549035:mogamulizumab